HEXABRIX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXABRIX is an injectable small-molecule contrast agent approved in 1985 by Guerbet for radiographic imaging procedures. The product is used to enhance visualization in diagnostic imaging studies, enabling clinicians to differentiate anatomical structures and detect pathology.
LOE Approaching
As LOE approaches, the brand team is likely consolidating; career opportunities skew toward defending market share against generics rather than growth-stage expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HEXABRIX offers limited career growth potential due to its mature lifecycle stage and approaching loss of exclusivity. Roles on this product focus on sustaining current market position and managing transition to generic competition rather than innovation or market expansion.
Brand ManagerSales Representative
Worked on HEXABRIX at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.